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ABSTRACT: The amyloid plaques associated with
Alzheimer’s disease (AD) comprise ﬁbrillar amyloid-β
(Aβ) peptides as well as non-protein factors including
glycosaminoglycan (GAG) polysaccharides. GAGs aﬀect
the kinetics and pathway of Aβ self-assembly and can
impede ﬁbril clearance; thus, they may be accessory
molecules in AD. Here we report the ﬁrst high-resolution
details of GAG−Aβ ﬁbril interactions from the perspective
of the saccharide. Binding analysis indicated that the GAG
proxy heparin has a remarkably high aﬃnity for Aβ ﬁbrils
with 3-fold cross-sectional symmetry (3Q). Chemical
synthesis of a uniformly 13C-labeled octasaccharide heparin
analogue enabled magic-angle spinning solid-state NMR of
the GAG bound to 3Q ﬁbrils, and measurements of
dynamics revealed a tight complex in which all saccharide
residues are restrained without undergoing substantial
conformational changes. Intramolecular 13C−15N dipolar
dephasing is consistent with close (<5 Å) contact between
GAG anomeric position(s) and one or more histidine
residues in the ﬁbrils. These data provide a detailed model
for the interaction between 3Q-seeded Aβ40 ﬁbrils and a
major non-protein component of AD plaques, and they
reveal that GAG−amyloid interactions display a range of
aﬃnities that critically depend on the precise details of the
ﬁbril architecture.
Alzheimer’s disease (AD) is characterized pathologically by anaccumulation of insoluble plaques within the extracellular
spaces of brain tissue. The main protein constituents of AD
plaques are the 40- and 42-residue amyloid-β peptides, Aβ40 and
Aβ42, derived from the amyloid precursor protein. The
relationship between Aβ self-assembly and disease has not been
elucidated, but the development of drugs that lower the
propensity of Aβ peptides to self-assemble or reduce the
aggregate concentration is a therapeutic goal.1 Aβ amyloid
plaques in the brain are highly heterogeneous, comprising ﬁbrous
proteins of diﬀerent structural organizations,2 metal ions, nucleic
acids, and glycosaminoglycans (GAGs),3 the linear sulfated
polysaccharide components of proteoglycans. GAGs accelerate
Aβ polymerization4 and increase ﬁbril resistance to proteolytic
degradation.5 The recent clinical failure of drugs that inhibit Aβ
aggregation in vitro6may reﬂect, in part, the role ofmolecules such
as GAGs in the development and stabilization of amyloid in the
brain.Work focusing onGAGs has revealed a complicated picture
of interactions with protein networks, with low binding speciﬁcity
and high redundancy among heterogeneous saccharide units.7
We previously detected a GAG binding site at the surface of
ﬁbrillar MAβ40 (an Aβ40 homologue with an N-terminal
methionine) from heparin-induced peptide chemical shift
perturbations measured using cross-polarization magic-angle
spinning (CP-MAS) solid-state NMR (SSNMR).8 In this and
previous studies, heparin was employed as a proxy for the highly
sulfated domain of heparan sulfate (HS) commonly associated
with amyloid plaques and sharing the same disaccharide units as
heparin.9 Aβ40 ﬁbrils are polymorphic, and ﬁbril strains having
approximately 2-fold (2A) or 3-fold (3Q) cross-sectional
symmetry can be selected by seeding and morphologically
conﬁrmed by SSNMR.8,10 Previously, we developed an assay to
quantify heparin binding which involves sedimentation of bound
heparin with ﬁbrils and quantiﬁes unbound heparin by addition of
heparinase enzyme, creating a spectroscopically active product.8
We found that heparin binds with surprisingly higher aﬃnity to
MAβ40 3Q ﬁbrils than toMAβ40 2A ﬁbrils, and the SSNMRdata
suggest that heparin recognizes the junctions of the triangular
cross-section that is unique in the structures of 3Q ﬁbrils (Figure
S1).8
Here we show, in addition, that de novo MAβ40 ﬁbrils
assembled without seeding, a peptide comprised of Aβ residues
16−22 (KLVFFAE), human amylin (hIAPP)which is 47%similar
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in sequence to Aβ40, and a uniform morphology of MAβ42
ﬁbrils11 bind weakly to low-molecular-weight heparin (LMWH)
(Figures 1A and S2). These binding diﬀerences suggest a unique
relationship between 3Q ﬁbrils in particular and heparin, but the
origin of this speciﬁc relationship requires a full molecular-level
understanding of the 3Q ﬁbril−heparin interaction. Whether all
heparin residues lie in contact with speciﬁc amino acids (Figure
S1, top), or whether part of heparin lies away from the ﬁbril
surface (Figure S1, bottom), is not known. Here, synthesis of a
uniformly 13C-labeled octasaccharide heparin analogue
([U-13C]OHA) has enabled the detailed analysis of a GAG−
amyloid interaction for the ﬁrst time from the GAG perspective,
using CP-MAS SSNMR to observe the GAG bound to insoluble
3Q MAβ40 ﬁbrils.
We assessed the aﬃnities of heparin-derived polysaccharides of
diﬀerent length (dp4−dp18) for 3Q-seededMAβ40 ﬁbrils, using
the GAG binding assay described above and in ref 8. All heparin
fragments show saturable binding, consistentwith speciﬁcGAG−
ﬁbril interactions, and an apparent Bmax < 20 μM (Figures S3 and
S4). Heparin tetrasaccharide (dp4) shows the lowest binding
aﬃnity (Kd = 78 ± 17 μM), and although the larger fragments
show slight increases in binding aﬃnity, there is no signiﬁcant
diﬀerence between the Kd values for dp6−dp18 (Figures 1B and
S3). An octasaccharide (dp8; Kd = 43± 11 μM) was thus chosen
as a representative GAG to investigate amyloid binding in
structural detail. [U-13C]OHA (synthesized as in ref 12) consists
of alternating 1−4-linked, 6-O-sulfated, N-sulfated α-D-glucos-
amine [amino sugar (A)], and 2-O-sulfated α-L-iduronic acid (I)
units, with a 1,6-anhydro ether bridge in the terminal iduronate
ring (Figure 1D)maintaining a closed ring at the former reducing
terminus. A 2-fold molar excess of [U-13C]OHA was added to
15N-labeled MAβ40 ﬁbrils prepared by seeding with the 3Q
morphology.10 13C spectra of [U-13C]-labeled seeded ﬁbrils
resembled previously published MAβ40 3Q spectra,8 verifying
the ﬁbril morphology. Transmission electronmicroscopy (TEM)
conﬁrms that the linear unbranched ﬁbrils aremaintained (Figure
1C). The ﬁbrils were isolated by centrifugation, and the pellet,
estimated to contain 600 nmol ofMAβ40 and 170 nmol of bound
[U-13C]OHA, was analyzed by 13C CP-MAS SSNMR, revealing
signature peaks (60−102 ppm) from the octasaccharide. Under
CP-MAS, signals are detected only from nuclei in environments
where molecular dynamics are too slow (<104 Hz) to average the
1H−13C dipolar couplings (e.g., ref 14). Hence, the observed
[U-13C]OHA peaks must arise from octasaccharide associated
with the insoluble ﬁbrils. Although the peaks are too broad to
resolve residue-speciﬁc detail, a two-dimensional 13C−13C
SSNMR spectrum (Figure 2B) and tentative peak assignments
from aHSQC solution spectrum (Figure S5) enabled resonances
to be attributed to positions on the glucosamine and iduronate
residues. The changes in chemical shifts upon binding are small
(Table S1), which argues against major conformational
perturbations that can result in signiﬁcant changes in chemical
shifts, particularly if hydrogen bonding is disrupted.13
The bound saccharide dynamics were assessed further by CP-
MASNMR. A 13C refocused INEPT15 SSNMR spectrum at 4 °C,
which detects only long-lifetime coherences from highly mobile
groups, is dominated by peaks from MAβ40 (12−68 ppm), with
very weak signals from 68 to 78 ppm that may arise from a small
mobile fraction of bound or unbound [U-13C]OHA. The absence
of peaks around 100 ppm fromA-1 and I-1 implies that large-scale
motional ﬂuctuations, involving the entire octasaccharide back-
bone, do not occur. Measurements of motionally sensitive cross-
polarization rates RHC and rotating frame relaxation rates R1ρH for
the CH groups at 4 °C (Figure 3B; original data in Figure S6) are
typical of organic solids with restricted molecular dynamics.16
The rates remain essentially the same at −25 °C, which suggests
that the saccharide dynamics are similarly impaired in the frozen
and non-frozen states. Increased dynamics from −25 to 4 °C
(including faster rates of chemical exchange between free and
bound states) would result in slower cross-polarization and
relaxation rates (see SI and Figure S7 for further discussion).17
Order parameters SCH determined from octasaccharide
13C−1H
dipolar couplings (Figure S8) are near the rigid-limit value of 1.0
and consistent with low-amplitude motions of ring C−H bonds
Figure 1.GAG binding to amyloid ﬁbrils. (A) Binding aﬃnities of ﬁbrils
to low-molecular-weight heparin (LMWH, dp16). Curves were obtained
by nonlinear least-squares ﬁtting of a Hill function. (B) Apparent
dissociation constants Kd for MAβ40 3Q ﬁbrils binding heparin
fragments of diﬀerent degrees of polymerization (dp4−dp18). (C)
TEM image of 3Q ﬁbrils co-sedimented with [U-13C]OHA. (D)
Chemical structure of [U-13C]OHA. Figure 2. 13C CP-MAS SSNMR spectra of the [U-15N] 3Q ﬁbril−
[U-13C]OHA complex. (A) Experimental spectrum (black) at 4 °C, with
assignments, and a simulated spectrum from the solution chemical shifts
(red). (B) 2D symmetrized 13C−13C spectrum recorded with a DARR
mixing time of 20 ms (black) and an unsymmetrized spectrum at 50 ms
mixing time (red).
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on the sub-millisecond time scale. These data strongly suggest
that all octasaccharide residues are restrained by intimate contact
with MAβ40.
We next sought to identify close contacts between [U-15N]-
MAβ40 ﬁbrils and [U-13C]OHA. The 15N CP-MAS spectrum of
3Q ﬁbrils alone shows sharp peaks from Arg and Lys side chains
and His 15Nδ1/ε2 resonances (160−180 ppm) that are much
broader, possibly due to proton exchange or tautomeriza-
tion.11The 15N 1D and 1H−15N HETCOR spectra of the
[U-13C]OHA−ﬁbril complex reveal the appearance of a new
sharp peak at∼161 ppm (Figure 3C,D) and several sharper peaks
assigned to backbone and Asn/Gln amides, which suggest a
general ordering of the ﬁbrils in the presence of the GAG, and a
new sharp peak at ∼161 ppm attributed to His Nε2. Histidine
15Nε2 and 15Nδ1 chemical shifts formodel tripeptides are 173−176
ppm for the acidic form (and 1Hε2/1Hδ1 shifts are >10 ppm) and
∼231 and 181 ppm for the conjugate base.18 Here the peak at 161
ppmmay reﬂect the stabilization of protonated His ring(s) by the
octasaccharide CO2
− and SO3
− groups. A non-selective15N-
observed, 13C-dephased rotational-echo double-resonance (15N-
{13C}REDOR) experiment (Figure 3E) showed weak dephasing
of peptide amide resonances (112−130 ppm) and possibly also of
His resonances, although the signal-to-noise ratio is rather poor.
Dipolar dephasingof resonances assigned toArg, Lys, andGlywas
not observed above the noise. Dephasing was not quantiﬁed
because of uncertainties arising from there being a 3-fold excess of
ﬁbrils over [U-13C]OHA and because of small contributions from
13C at natural abundance. A 13C-observed frequency-selective
rotational-echo double-resonance (FSR) experiment19 was used
to detect speciﬁc 15N−13C dipolar interactions between His side-
group 15Nδ1/ε2 sites and saccharide C-1 carbons in the 97−100
ppm region.The observed dipolar dephasing (S/S0 = 0.72±0.15)
corresponds to a 13C−15N distance of 3.1−4.6 Å for a single spin
pair, consistent with His−[U-13C]OHA interactions. The
SSNMR measurements provide new clues about the selectivity
of heparin-derived GAGs for MAβ40 ﬁbrils with 3Qmorphology
and highlight the role of saccharide interactions with histidines
(H6, H13, and/or H14) in the formation of the GAG−3Q ﬁbril
complex. We conﬁrmed that GAG sulfate moieties are critically
important for this interaction by showing that fully desulfated
heparin does not bind to the ﬁbrils (Figure S9A). GAG sulfate
groups may thus interact withH6 andH13 if the GAG recognizes
the junctions of the unique triangular cross-section of the 3Q
morphology, whereas interactions with H14 would require
binding to the outer surface common to both 2A and 3Q
morphologies (Figures S10 and S11). The higher aﬃnity of
heparin for 3Q than for 2A ﬁbrils favors the preferential
recognition of the unique junctions of 3Q. A 3Q-seeded variant
of MAβ40, H6F, shows reduced heparin binding (Kd = 100 ± 14
μM, compared to 43 μM for dp8, Figures S9B and S10), which
implies that H6 is involved in, although not essential for, complex
formation. [U-13C]OHAmay bind tightly if its anionic groups are
oriented approximately parallel to the ﬁbril long axis, allowing
interactions with polycationic ladders of residues from the
repeating peptide units. Computational molecular docking of
OHA in the cleft at the triangular junctions, restrained by a
distance of <4.0 Å between Nδ1/ε2 sites of appropriate H6 rings in
the ﬂexible N-terminal region and octasaccharide C-1 positions,
allows for ionic interactions between sulfate and imdazo groups of
H6 and H13 on opposite faces (Figure 4A), as well as hydrogen
bonding with N27 (which previously showed >1 ppm chemical
shift perturbations upon heparin binding8), acting in concert to
strengthen the interaction between peptide and saccharide
further. The presence of Asn residues alongside cationic residues
Figure 3. SSNMR analysis of [U-13C]OHA interactions with [U-15N]MAβ40 ﬁbrils. (A) CP-MAS spectrum of ﬁbrils alone (top), overlaid with the
spectrum from Figure 2A (red) and a refocused INEPT spectrum of the complex of ﬁbrils and [U-13C]OHA (bottom). (B) Cross-polarization rate
constantsRHC andproton rotating frame relaxation ratesR1ρHof [U-
13C]OHAbound to theﬁbrils. (C) 15NCP-MAS spectra ofﬁbrils alone (top) andwith
[U-13C]OHA (bottom). Neut = neutral; prot. = protonated; SS = spinning sideband; NT = N-terminal amine. (D) 1H−15N HETCOR spectrum. (E,F)
Measurements of dipolar couplings between ﬁbrils and [U-13C]OHA at −25 °C. (E) Full-echo (S0) and dephased-echo (S) 15N{13C} REDOR spectra
(8.3 ms dephasing) and diﬀerence (Δ). (F) 13C{15N} FSR spectra (6.4 ms dephasing) obtained with selective refocusing applied at the frequencies of
15Nδ1/ε2 and C-1 of [U-13C]OHA (red) and a full-echo spectrum (black).
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has been posited recently as a characteristic of GAG binding sites
in proteins.20The octasaccharide in a broadly linear conformation
bears O- andN-linked SO3
− groups thatmatch approximately the
periodicity of repeating side groups (∼4.7 Å) (Figure 4B). This,
andour bindingdata onotherﬁbril types (Figure 1A), suggest that
GAG−3Q interactions are more speciﬁc than mere electrostatic
patterning. Instead, the structure of the 3Q ﬁbril corners localizes
multiple charged and hydrogen-bonding residues in a favorable
orientation, providing a tight and speciﬁc binding site for heparin
(Figure S11). The involvement of histidine residues in this
interaction suggests that disease states manifesting local pH
changes could enhance GAG−ﬁbril interactions, leading to
altered rates of disease progression. Fibrils with diﬀerent binding
modes and aﬃnities may rationalize the array of phenotypes that
are present in AD and the range of time scales over which the
disease progresses.
The work presented provides the ﬁrst glimpse of a GAG chain
binding tightly and oﬀers rationalization for the quantiﬁable and
surprisingly speciﬁc aﬃnity for a well-deﬁned morphology of
Aβ40 ﬁbrils. A 3-fold conformation of Aβ has been isolated and
puriﬁed from human brain tissue, underscoring the relevance of
this structural motif in disease.2 These results reveal that while
GAGs are commonly found associated with amyloid plaques,
GAG−ﬁbril interactions show remarkable speciﬁcity, which may
inﬂuence the varied properties of amyloid ﬁbrils in disease.
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